ArriVent BioPharma, Inc. - 8-K Filing
ArriVent BioPharma's Phase 3 FURVENT trial of firmonertinib in first-line EGFR exon 20 insertion mutant NSCLC did not meet its primary endpoint of progression-free survival by blinded independent central review, though secondary endpoints showed clinical benefit. (Items: 7.01 Regulation FD Disclosure, 8.01 Other Events)
Tickers: $AVBP